162 related articles for article (PubMed ID: 32900772)
1. Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease.
Alam IS; Simonetta F; Scheller L; Mayer AT; Murty S; Vermesh O; Nobashi TW; Lohmeyer JK; Hirai T; Baker J; Lau KH; Negrin R; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4780-4790. PubMed ID: 32900772
[TBL] [Abstract][Full Text] [Related]
2. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
3. ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.
Xiao Z; Alam IS; Simonetta F; Chen W; Scheller L; Murty S; Lohmeyer JK; Ramos TL; James ML; Negrin RS; Gambhir SS
Blood Adv; 2022 Aug; 6(16):4782-4792. PubMed ID: 35790103
[TBL] [Abstract][Full Text] [Related]
4. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
5. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Valzasina B; Guiducci C; Dislich H; Killeen N; Weinberg AD; Colombo MP
Blood; 2005 Apr; 105(7):2845-51. PubMed ID: 15591118
[TBL] [Abstract][Full Text] [Related]
6. Central Roles of OX40L-OX40 Interaction in the Induction and Progression of Human T Cell-Driven Acute Graft-versus-Host Disease.
Tripathi T; Yin W; Xue Y; Zurawski S; Fujita H; Hanabuchi S; Liu YJ; Oh S; Joo H
Immunohorizons; 2019 Mar; 3(3):110-120. PubMed ID: 31240276
[TBL] [Abstract][Full Text] [Related]
7. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Akiba H; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 2000 Apr; 95(7):2434-9. PubMed ID: 10733518
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
[TBL] [Abstract][Full Text] [Related]
9. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
10. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Imaging OX40
Wen G; Lei H; Qi B; Duan S; Xiao Z; Han C; Xia Y; Jing C; Liu J; Li C
Mol Imaging Biol; 2023 Aug; 25(4):621-629. PubMed ID: 37012517
[TBL] [Abstract][Full Text] [Related]
12. Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Mo F; Watanabe N; Omdahl KI; Burkhardt PM; Ding X; Hayase E; Panoskaltsis-Mortari A; Jenq RR; Heslop HE; Kean LS; Brenner MK; Tkachev V; Mamonkin M
Blood; 2023 Mar; 141(10):1194-1208. PubMed ID: 36044667
[TBL] [Abstract][Full Text] [Related]
13. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
Streeter PR; Zhang X; Tittle TV; Schön CN; Weinberg AD; Maziarz RT
Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
17. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
18. Regulation of OX40 gene expression in graft-versus-host disease.
Miura Y; Thoburn CJ; Bright EC; Arai S; Hess AD
Transplant Proc; 2005; 37(1):57-61. PubMed ID: 15808546
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
20. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
